Lupin launches Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03 per cent and 0.06 per cent in the US Read more
Lupin announces presentation of phase 1 data on LNP7457 (PRMT5 inhibitor) at the ASCO – Annual Meeting 2025 Read more
Lupin and SteinCares enter into License and Supply Agreement for Ranibizumab in Latin America Read more